JAZZ - Jazz Pharmaceuticals: Undervalued Mid-Sized Pharma Has Assets To Make Up For Falling Xyrem Sales
Investment Thesis
Jazz Pharmaceuticals 5-year share price performance. Source: TradingView.
As we can see above Jazz Pharmaceuticals' (JAZZ) stock is trading some way below its starting 2020 starting price of $152, even further below the $178 the stock traded at in mid-2018, and nearly 50% below its 2016 all time high of $194.
Jazz struck gold back in 2005 when it acquired the biotech Orphan Medical - which had won approval for its sodium oxybate treatment for narcolepsy, Xyrem - in a deal worth ~$125m in 2005. Xyrem has gone on to